Recent REVB News
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 09/03/2024 09:09:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/26/2024 08:25:36 PM
- Revelation Biosciences Inc. Announces Exercise of Warrants for $3.8 Million in Gross Proceeds • Business Wire • 08/21/2024 09:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/19/2024 08:05:12 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024 • Business Wire • 08/09/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:11:50 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 07/29/2024 04:15:14 AM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 07/19/2024 08:02:22 PM
- Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity • Business Wire • 06/24/2024 01:00:00 PM
- Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini • Business Wire • 06/13/2024 01:21:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2024 • Business Wire • 05/10/2024 08:52:00 PM
- Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2023 • Business Wire • 03/22/2024 08:15:00 PM
- Revelation Biosciences Inc. Gives Oral Presentation at Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 03/13/2024 01:00:00 PM
- Revelation Biosciences Inc. to Participate in a Virtual Fireside Chat at the 36th Annual Roth Conference • Business Wire • 03/12/2024 01:00:00 PM
- Revelation Biosciences Inc. Announces Commencement of First in Human Phase 1 Clinical Study of Gemini • Business Wire • 03/04/2024 02:00:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 01:12:05 AM
- Revelation Biosciences Inc. Receives Invitation to Give an Oral Presentation at The 29th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2024) • Business Wire • 02/13/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:01:23 PM
- Revelation Biosciences Inc. Announces Closing of $6.2 Million Public Offering • Business Wire • 02/05/2024 09:41:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/02/2024 09:06:10 PM
- Revelation Biosciences Inc. Announces Pricing of $6.2 Million Public Offering • Business Wire • 02/01/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 10:21:32 PM
- Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/30/2024 08:32:42 PM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM
Integrated Ventures Acquires 51% Stake In GetTrim.Com (TM), Telemedicine Platform With Focus On Expansion Into Booming GLP-1 Powered Weight Loss Market • INTV • Sep 4, 2024 8:45 AM
Avant Technologies Announces Strategic Review Process Intended to Maximize Shareholder Value • AVAI • Sep 4, 2024 8:00 AM